The Mobi-C is a cobalt chromium alloy and polyethylene prosthesis. It is designed to be bone-sparing and serve as an alternative to fusion.
LDR completed the rigorous process of obtaining FDA pre-market approval, including conducting a 24-month clinical study. Results showed the Mobi-C had a success rate of 69.7 percent compared with ACDF’s rate of 37.4 percent.
Patients in the study were also able to return to work at 45.9 days with the Mobi-C compared with 66.8 days for ACDF.
More Articles on Devices:
Interventional Spine Receives Minimally Invasive Fusion Device Patent
IlluminOss Medical Names Dwayne Montgomery as Senior Vice President of Sales
InVivo Therapeutics Appoints Interim CEO, CFO to Replace Francis Reynolds
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
